The study focuses on adults who have Chronic rhinosinusitis with nasal polyps, a condition where the lining of the nose and sinuses stays inflamed for a long time and small growths called polyps develop, making breathing difficult and causing a runny nose or loss of smell. Participants will receive either the investigational medicine itepekimab, given as a subcutaneous injection (a shot under the skin), or a matched placebo that looks the same but does not contain the active drug.
The main goal is to assess the long‑term safety and tolerability of the medicine, meaning researchers will watch for any side effects or problems over an extended period. After the initial treatment period, participants will continue to attend regular visits where doctors will ask about health changes, perform a simple nasal examination, and may take a small blood sample to check drug levels. The study also records whether participants need additional treatments such as a short course of a systemic corticosteroid (a pill that reduces inflammation throughout the body) or sinus surgery.
1screening and enrollment
after joining the study, you undergo screening procedures to confirm eligibility based on your chronic rhinosinusitis with nasal polyps condition.
the screening includes medical history review, physical examination, and baseline measurements that will be used for later comparisons.
2baseline visit
at the baseline visit, detailed assessments of nasal polyps, symptom scores, and laboratory tests are performed.
the results establish your starting point for evaluating safety and tolerability during the extension study.
3randomization and first injection
you are randomly assigned to receive either itepekimab or a matched placebo. the assignment is double‑blinded, meaning neither you nor the study staff know which product you receive.
itepekimab is administered by subcutaneous injection (injection under the skin) using a pre‑filled syringe. the labeled dose is 00 mg, as defined by the protocol.
the matched placebo is administered in the same manner, without active drug.
4regular injection visits
you return to the study site for additional injections according to the schedule defined in the protocol. each visit includes the same subcutaneous administration of either itepekimab or placebo.
the exact interval between injections (for example, every 4 weeks) is specified by the study protocol, but is not detailed in the provided information.
5safety monitoring visits
at each visit, health professionals assess you for any adverse events, including serious or treatment‑emergent events.
laboratory tests may be performed to monitor blood chemistry and immune response, including detection of anti‑drug antibodies.
6interim assessments
periodically, endoscopic examination of nasal polyps and symptom questionnaires are repeated to track changes from the baseline of the parent studies.
functional itepekimab concentration in serum may be measured to evaluate drug exposure.
7final visit and study end
at the conclusion of the extension period, a final assessment is performed, including safety evaluation, endoscopic examination, and collection of any remaining study data.
after the final visit, the study drug is discontinued and you are no longer required to attend study visits.
Who Can Join the Study?
You must have chronic rhinosinusitis with nasal polyps (CRSwNP) and have finished a previous 52‑week study of the medicine itepekimab (study IDs EFC18418 or EFC18419).
Your last visit in that previous study (the end‑of‑treatment (EOT) visit) must have taken place no more than 5 days before you come to this study.
Both men and women are allowed to take part.
If you are a woman, you must not be pregnant or breastfeeding.
If you are a woman who could become pregnant (woman of childbearing potential), you must agree to follow the study’s birth‑control instructions during the treatment period and for at least 20 weeks after the last dose.
Who Cannot Join the Study?
Having been diagnosed with a malignancy (a type of cancer) during the earlier study, unless it was a skin cancer called squamous cell carcinoma or basal cell carcinoma.
Having any opportunistic infection (an infection that occurs when the immune system is weakened) during the earlier study, such as tuberculosis (TB) or other infections that suggest the immune system is not working well.
Having had a severe allergic reaction (anaphylactic reaction) or a whole‑body allergic reaction (systemic allergic reaction) that was linked to the study drug (IMP) and needed treatment during the earlier study.
Any other situation that caused the study drug (IMP) to be stopped permanently and early in the earlier trials.
Itepekimab is a laboratory‑made protein given as a small injection under the skin. It works by blocking a part of the immune system that can cause swelling and growth of tissue in the nose. In this study, adults whose chronic sinus condition with nasal polyps was not well‑controlled received itepekimab to see if it remains safe and well‑tolerated when used for a long time. The medication is supplied as a clear liquid in a ready‑to‑use pre‑filled syringe.
Chronic rhinosinusitis with nasal polyps – Chronic rhinosinusitis with nasal polyps is a long‑lasting inflammation of the nasal passages and sinuses that includes the growth of soft tissue lumps called polyps. The condition causes swelling, blockage, and excess mucus in the nose and sinus cavities. Over time the polyps can become larger, making it harder to breathe through the nose and leading to a feeling of fullness in the face. The inflammation may flare up repeatedly, causing periods of increased congestion, runny nose, and reduced sense of smell. Symptoms often persist for months or years, and the condition can gradually worsen if the underlying inflammation continues.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Czechia 
Denmark 
Finland 
France 
Germany 
Hungary 
Italy 
Poland 
Portugal 
Romania 
Spain 
Sweden 
The Netherlands